Dong Hai-Long, Sui Yan-Fang, Li Zeng-Shan, Qu Ping, Wu Wen, Ye Jing, Zhang Xiu-Min, Lu Shao-Ying
Department of Pathology, Fourth Military Medical University, Xi'an 710032, Shaanxi, China.
Cancer Lett. 2004 Aug 10;211(2):219-25. doi: 10.1016/j.canlet.2004.02.013.
MAGE-n is a new member of MAGE gene family and has been demonstrated closely associated with hepatocellular carcinoma (HCC). In this study, MAGE-n-derived peptide-specific cytotoxic T lymphocytes (CTL) were induced from the peripheral blood mononuclear cells of healthy donors by multiple stimulations with HLA-A2-restricted MAGE-n peptide-pulsed T2 cells. The induced CTLs exhibited specific lysis against T2 cells pulsed with the peptide and HLA-A2+ HCC cells expressing MAGE-n, while HLA-A2+ HCC cell lines that did not express MAGE-n could not be recognized by the CTLs. The peptide-specific activity was inhibited by anti-MHC class I monoclonal antibody. These results suggested the MAGE-n peptide could be a potential target of specific immunotherapy for HLA-A2 patients with HCC.
MAGE-n是MAGE基因家族的一个新成员，已被证明与肝细胞癌（HCC）密切相关。在本研究中，通过用HLA-A2限制性MAGE-n肽脉冲的T2细胞多次刺激，从健康供体的外周血单个核细胞中诱导出MAGE-n衍生肽特异性细胞毒性T淋巴细胞（CTL）。诱导的CTL对用该肽脉冲的T2细胞和表达MAGE-n的HLA-A2+HCC细胞表现出特异性裂解，而不表达MAGE-n的HLA-A2+HCC细胞系不能被CTL识别。肽特异性活性被抗MHC I类单克隆抗体抑制。这些结果表明，MAGE-n肽可能是HLA-A2型HCC患者特异性免疫治疗的潜在靶点。
